Amgen 2002 Annual Report Download - page 71

Download and view the complete annual report

Please find page 71 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Joseph P. Miletich
Senior Vice President, Research
and Preclinical Development
George J. Morrow
Executive Vice President
Worldwide Sales and Marketing
Richard D. Nanula
Executive Vice President, Finance,
Strategy and Communications, and
Chief Financial Officer
Steven M. Odre
Senior Vice President
General Counsel and Secretary
Roger M. Perlmutter
Executive Vice President
Research and Development
Beth C. Seidenberg
Senior Vice President
Development
Kevin W. Sharer
Chairman of the Board, Chief
Executive Officer and President
Board of Directors
David Baltimore
President
California Institute of Technology
Frank J. Biondi, Jr.
Senior Managing Director
WaterView Advisors LLC
Jerry D. Choate
Retired Chairman and
Chief Executive Officer
The Allstate Corporation
Edward V. Fritzky
Retired Chairman and
Chief Executive Officer
Immunex Corporation
Frederick W. Gluck
Retired Vice Chairman
Bechtel Group, Inc.
Franklin P. Johnson, Jr.
General Partner
Asset Management Partners
Board of Directors and Executive Officers
Stockholder Information
Corporate Office
One Amgen Center Drive
Thousand Oaks, California 91320-1799
(805) 447-1000
SEC Form 10-K
A copy of the Company’s Annual Report on Form 10-K for the year ended
December 31, 2002, filed with the Securities and Exchange Commission, is
available without charge upon written request to Corporate Secretary, Amgen,
One Amgen Center Drive, Thousand Oaks, California 91320-1799; by calling
(800) 84-AMGEN; or by accessing the Company’s website at www.amgen.com.
Transfer Agent and Registrar
American Stock Transfer & Trust Company
59 Maiden Lane
New York, New York 10038
Stockholder Inquiries
Inquiries related to stock transfers or lost certificates should be directed to
American Stock Transfer & Trust Company, (800) 937-5449 or (212) 936-5100.
General information regarding the Company and recent news releases can be
obtained by contacting Amgen’s automated stockholder information line at
(800) 84-AMGEN or by accessing the Company’s website at www.amgen.com.
Independent Auditors
Ernst & Young LLP, Los Angeles, California
Annual Meeting
The Annual Meeting will be held on Thursday, May 15, 2003, at 10:30 a.m. at
the Omni Interlocken Resort, 500 Interlocken Blvd., Broomfield, Colorado
80021.
2002 2001
High Low High Low
4th Quarter $51.75 $43.66 $68.49 $56.03
3rd Quarter 48.54 31.07 65.66 54.01
2nd Quarter 61.39 37.80 70.02 51.51
1st Quarter 62.48 54.33 74.19 54.94
Steven Lazarus
Managing General Partner
ARCH Venture Partners, L.P.
Gilbert S. Omenn
Professor of Internal Medicine,
Human Genetics and Public Health,
University of Michigan
Judith C. Pelham
President
and Chief Executive Officer
Trinity Health
Adm. J. Paul Reason,
USN (Retired)
President and
Chief Operating Officer
Metro Machine Corporation
Donald B. Rice
President and
Chief Executive Officer
Agensys, Inc.
Kevin W. Sharer
Chairman of the Board, Chief
Executive Officer and President
Amgen Inc.
Patricia C. Sueltz
Executive Vice President
Software Systems Group
Sun Microsystems, Inc.
Executive Officers
Fabrizio Bonanni
Senior Vice President
Quality and Compliance
Hassan Dayem
Senior Vice President and
Chief Information Officer
Dennis M. Fenton
Executive Vice President
Process Development,
Operations and Quality
Brian M. McNamee
Senior Vice President
Human Resources
Price Range of Common Stock
The Company’s common stock trades on The NASDAQ Stock Market under the
symbol AMGN. No cash dividends have been paid on the common stock to
date, and the Company currently intends to retain any earnings for development
of the Company’s business and for repurchases of its common stock.
The following table sets forth, for the fiscal periods indicated, the range of high
and low closing sales prices of the common stock as quoted on The NASDAQ
Stock Market for the years 2002 and 2001:
Trademarks Listed in This Report
Amgen, Aranesp®, EPOGEN®, Kineret®, Neulasta™, and NEUPOGEN®
are trademarks of Amgen Inc. ENBREL® is a trademark of Amgen’s subsidiary,
Immunex Corporation.
Hotlines
Customer Service Hotline (800) 28-AMGEN
Investor Materials Hotline (800) 84-AMGEN
Jobline (800) 446-4007
Medical Information Connection (800) 77-AMGEN
Reimbursement Hotline (800) 272-9376
Clinical Safety Hotline (800) 835-2879